Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease
Status:
NOT_YET_RECRUITING
Trial end date:
2028-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects.
The study will assess any thinking or attention problems participants may have both before taking this drug and after. Additionally, the study will assess the decision-making process of the caregiver that may influence using this drug or not.
Primary Objective:
Assess the feasibility, acceptability, and adherence to MPH treatment in children with SCD and EF deficits.
Secondary Objective:
Evaluate neurobehavioral and safety outcomes following MPH treatment.
Exploratory Objective:
Evaluate decision-making and determinants influencing methylphenidate utilization among parents.